Santen Pharmaceutical Co., Ltd. (TYO:4536)
1,880.50
-35.50 (-1.85%)
Aug 19, 2026, 3:30 PM JST
Santen Pharmaceutical Revenue
Santen Pharmaceutical had revenue of 68.96B JPY in the quarter ending June 30, 2026, with 0.32% growth. This brings the company's revenue in the last twelve months to 291.84B, down -0.72% year-over-year. In the fiscal year ending March 31, 2026, Santen Pharmaceutical had annual revenue of 291.62B, down -2.79%.
Revenue (ttm)
291.84B
Revenue Growth
-0.72%
P/S Ratio
2.11
Revenue / Employee
73.55M
Employees
3,968
Market Cap
615.40B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2026 | 291.62B | -8.38B | -2.79% |
| Mar 31, 2025 | 300.00B | -1.96B | -0.65% |
| Mar 31, 2024 | 301.97B | 22.93B | 8.22% |
| Mar 31, 2023 | 279.04B | 12.78B | 4.80% |
| Mar 31, 2022 | 266.26B | 16.65B | 6.67% |
| Mar 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Otsuka Holdings | 2.62T |
| Astellas Pharma | 2.27T |
| Daiichi Sankyo Company | 2.22T |
| Chugai Pharmaceutical | 1.34T |
| Kyowa Kirin | 529.80B |
| Ono Pharmaceutical | 504.41B |
| JCR Pharmaceuticals | 41.45B |
| Perseus Proteomics | 146.53M |
Santen Pharmaceutical News
- 3 years ago - Santen Pharmaceutical upgraded to Buy from Neutral at Citi - TheFly